The Pharmacogenetics of Optimal Warfarin Therapy in Chinese Patients After Heart Valve Replacement.
NCT ID: NCT02710747
Last Updated: 2016-03-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
500 participants
INTERVENTIONAL
2015-01-31
2016-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To value the accuracy of warfarin pharmacogenomics algorithm by the algorithm calculated dose and actual dose in the Chinese patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Study of Warfarin Maintenance Dose in Chinese Patients
NCT01855737
Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients
NCT01610141
Individualized Administration of Warfarin by Polymorphisms of VKORC1 and CYP2C9 Genes
NCT03797534
Genotype-guided Versus Standard for Warfarin Dosing
NCT03479684
Genotype-guided Warfarin Individualized Treatment
NCT02211326
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Genetic Group
Dose (mg/week) = \[5.6044 - 0.02614 × Age \[in years\] + 0.0087 × Height \[cm\] + 0.0128 × Weight \[kg\] - 0.8677 × VKORC1 A/G -1.6974 × VKORC1 A/A - 0.5211 × CYP2C9 \*1/\*2 - 0.9357 × CYP2C9 \*1/\*3 - 1.0616 × CYP2C9 \*2/\*2 - 1.9206 × CYP2C9\*2/\*3 - 2.3312 × CYP2C9 \*3/\*3 - 0.1092 × Asian race - 0.5503 × amiodarone \]2
CYP2C9;VKORC1
Control Group
Dose for the first three days after operation will be 4.5mg/d.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CYP2C9;VKORC1
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* heart valve replacement
* VTE
Exclusion Criteria
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Guangdong Provincial People's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Guangdong General Hospital
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GDREC2014265H
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.